Abstract  Description  Claims  Drawing  Search report  Cited references 

Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene   [0006] 
The role of FLT3 in haematopoietic malignancies   [0006] 
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia   [0006] 
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies   [0006] 
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis   [0006] 
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease   [0006] 
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group   [0006] 
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse   [0006] 
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia   [0006] 
The Origin and Evolution of Mutations   [0006] 
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia   [0006] 
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412   [0006] 
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics   [0006] 
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia   [0006] 
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T3151-mutated BCR/ABL translocation   [0006] 
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)   [0006] 
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy   [0006] 
Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation   [0006] 
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia   [0006] 
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response   [0006] 
Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells   [0006] 
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies   [0006] 
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens   [0006] 
Pharmacotherapy A Pathophysiologic Approach 9/E   [0006] 
FLT3 mutations: biology and treatment   [0006] 
Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia   [0006] 
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia   [0006] 
Remington's Pharmaceutical Sciences   [0024]